Is Antiphospholipid Syndrome Inherited? Risk to Children
At a Glance
Antiphospholipid syndrome is not inherited in a simple pattern. A child may share genetic susceptibility, but most children of parents with APS remain healthy, and no validated test or percentage predicts who will develop antiphospholipid antibodies or clinical APS.
In this answer
4 sections
Familial antiphospholipid syndrome (APS) is not passed directly from a parent to a child in a simple or predictable way. Unlike conditions caused by a single mutated gene, familial APS involves a complex, incompletely understood genetic susceptibility [1][2]. While a child may inherit an increased tendency to develop autoimmune conditions, there is no reliable percentage, known inheritance pattern, or validated risk score to predict whether an individual child will ever develop antiphospholipid antibodies or clinical APS [3].
Understanding Complex Susceptibility
When we talk about “familial” APS, it means the condition has been observed to cluster in certain families [4][5]. However, APS is considered a polygenic condition, meaning multiple different genes interact with environmental factors to contribute to the overall risk [1].
Because of this genetic complexity, APS has uncertain penetrance. In practical terms, this means relatives may share some genetic susceptibility variants and environmental influences, but never develop antiphospholipid antibodies or the syndrome itself [2]. Medical research often proposes a second hit model to explain this: while a blood clot or pregnancy complication can happen without any identifiable trigger, environmental factors—such as an infection, surgery, pregnancy, or severe inflammation—can act as a “second hit” that activates the immune system and increases the chance of a complication [6][7].
What Does This Mean for Your Child’s Risk?
It is very common for parents with APS to worry about passing the condition to their children. However, the majority of children born to parents with APS are generally healthy [3].
When evaluating familial risk, it helps to understand the difference between genetic risk, temporary antibodies, and actual clinical APS.
| Stage | What It Means | Next Steps / Implications |
|---|---|---|
| Inherited Susceptibility | A child may inherit genetic variants that make their immune system slightly more prone to autoimmunity [1]. | No immediate medical action is required. Having a family history does not prove a child will develop APS. |
| Passive Maternal Antibodies | In newborns, maternal antibodies can cross the placenta. Roughly 30% of babies born to mothers with these antibodies may temporarily test positive at birth [8]. | These antibodies usually fade over months. Serious neonatal blood clots are exceedingly uncommon but not impossible [8]. |
| Developing Antibodies | The child’s own immune system produces antiphospholipid antibodies. | Antibodies alone are not APS [9]. They can be transient (e.g., after a childhood virus). |
| Clinical APS | The child has specific persistent antibodies (confirmed 12 weeks apart) and experiences a qualifying clinical event (like a blood clot) [10]. | Requires specialist management (e.g., pediatric hematology/rheumatology) [11]. |
Note for parents of newborns: If you have antiphospholipid antibodies, ask your obstetric and pediatric teams what monitoring is appropriate for your individual baby after birth [8].
Should Asymptomatic Children Be Tested?
If your child is completely healthy and shows no symptoms, medical guidelines generally do not recommend routine screening for antiphospholipid antibodies solely based on a family history of APS [12][13].
There are several reasons why preventative testing in healthy, asymptomatic children is usually discouraged:
- Antibodies can be transient: A child might temporarily develop antiphospholipid antibodies after a standard childhood viral infection [14]. To accurately assess risk, positive tests for specific antibodies (lupus anticoagulant, anticardiolipin, or anti-beta-2-glycoprotein I) must be confirmed with a second test at least 12 weeks later [10][15].
- Management complexities: Finding antibodies in a healthy child does not automatically mean they need blood thinners or preventative medication. While knowing about the antibodies might alter how doctors manage the child during high-risk situations (like surgery, severe illness, or prolonged immobility), routine testing often causes unnecessary anxiety without changing daily medical care [16].
- Antibodies alone are not APS: A diagnosis requires both the persistent laboratory markers and a qualifying clinical event [9].
When Testing is a Medical Emergency
If a child develops signs of a blood clot or stroke, this is a medical emergency. Seek immediate medical attention. Do not wait for an outpatient antibody test [11][17]. Warning signs include:
- Sudden one-sided weakness, numbness, or trouble speaking
- Severe, unusual headache or sudden vision changes
- Sudden shortness of breath or chest pain
- Unexplained, sudden swelling, pain, or redness in an arm or leg
For non-emergency situations, testing may be considered if a child is diagnosed with another autoimmune disease, like childhood-onset lupus, under the guidance of a pediatric specialist [11].
The Role of Genetic Counseling
Because APS is not caused by a single identifiable gene, genetic counselors cannot offer a simple DNA test to calculate your child’s exact risk of developing the syndrome [1]. However, if you have a striking pattern of early-onset or multiple autoimmune conditions in your family (like lupus or thyroid disease), consulting with a genetic counselor can help you map out your broader risk profile and document your family history accurately.
Common questions in this guide
Is antiphospholipid syndrome directly inherited from a parent?
What is my child’s chance of developing APS if I have it?
Should a healthy child be screened for APS because of family history?
Can maternal antiphospholipid antibodies affect a newborn?
Which symptoms in a child could signal a clot or stroke?
Can genetic counseling determine whether my child will develop APS?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Are there specific symptoms or warning signs I should watch for in my child that would warrant immediate emergency medical evaluation?
- 2.Should my child's care team be made aware of our family history of APS before any surgeries, severe illnesses, prolonged immobility, or future use of estrogen-containing medications?
- 3.Given our family's specific history, would you recommend a consultation with a pediatric rheumatologist or genetic counselor?
- 4.Which specific antibody tests were positive in my own diagnostic profile, and should I document this for my child's future medical records?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (17)
- 1
Genetics of Antiphospholipid Syndrome.
Ortiz-Fernández L, Sawalha AH
Current rheumatology reports 2019; (21(12)):65 doi:10.1007/s11926-019-0869-y.
PMID: 31807905 - 2
New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches.
Lopez-Pedrera C, Barbarroja N, Patiño-Trives AM, et al.
Frontiers in immunology 2019; (10()):764 doi:10.3389/fimmu.2019.00764.
PMID: 31040845 - 3
"APS pregnancy - The offspring".
Bitsadze V, Nalli C, Khizroeva J, et al.
Lupus 2020; (29(11)):1336-1345 doi:10.1177/0961203320947154.
PMID: 32752918 - 4
Familial Clustering of Antiphospholipid Syndrome.
Saadia A, Khan SH, Khan MD
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2019; (29(12)):1221-1224 doi:10.29271/jcpsp.2019.12.1221.
PMID: 31839101 - 5
Double trouble: myocardial infarction with non-obstructive coronary arteries as a presentation of Hughes syndrome in monozygotic twins.
Djokovic A, Stojanovich L, Stanisavljevic N, et al.
Lupus 2020; (29(5)):505-508 doi:10.1177/0961203320906267.
PMID: 32041501 - 6
Catastrophic antiphospholipid antibody syndrome as a first manifestation of primary antiphospholipid antibody syndrome in a middle-aged man.
Jafry NH, Mubarak M, Ahmed E, Akhtar F
CEN case reports 2020; (9(2)):152-158 doi:10.1007/s13730-020-00446-0.
PMID: 31989453 - 7
Acute adrenal insufficiency due to adrenal hemorrhage complicating colorectal surgery: Report of two cases and correlation with the antiphospholipid antibody syndrome.
Kolinioti A, Tsimaras M, Stravodimos G, Komporozos V
International journal of surgery case reports 2018; (51()):90-94 doi:10.1016/j.ijscr.2018.07.034.
PMID: 30145500 - 8
Neonatal antiphospholipid syndrome-associated thrombosis: Diagnostic pitfalls and therapeutic frontiers.
Tzatzadaki-Amantou E, Lianou A, Tsantes AG, et al.
Blood reviews 2026; 101433 doi:10.1016/j.blre.2026.101433.
PMID: 42731915 - 9
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.
Cohen H, Cuadrado MJ, Erkan D, et al.
Lupus 2020; (29(12)):1571-1593 doi:10.1177/0961203320950461.
PMID: 33100166 - 10
Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies.
Tufano A, Di Minno MND, Guida A, et al.
Seminars in thrombosis and hemostasis 2019; (45(5)):468-477 doi:10.1055/s-0039-1692702.
PMID: 31216589 - 11
Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects.
Islabão AG, Trindade VC, da Mota LMH, et al.
Paediatric drugs 2022; (24(1)):13-27 doi:10.1007/s40272-021-00484-w.
PMID: 34904182 - 12
The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.
Barbhaiya M, Zuily S, Naden R, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(10)):1687-1702 doi:10.1002/art.42624.
PMID: 37635643 - 13
Antiphospholipid syndrome and its role in pediatric cerebrovascular diseases: A literature review.
Sarecka-Hujar B, Kopyta I
World journal of clinical cases 2020; (8(10)):1806-1817 doi:10.12998/wjcc.v8.i10.1806.
PMID: 32518771 - 14
Antiphospholipid Antibody Testing: An Audit on Testing Practices in a Public Tertiary Care Center.
Mansory EM, Alahwal HM, Bahashwan SM, et al.
Journal of clinical medicine 2023; (13(1)) doi:10.3390/jcm13010243.
PMID: 38202249 - 15
Key Issues at the Forefront of Diagnosis and Testing for Antiphospholipid Syndrome.
Qiao J, Bailly J, Opie J
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2024; (30()):10760296241306751 doi:10.1177/10760296241306751.
PMID: 39692090 - 16
EULAR recommendations for the management of antiphospholipid syndrome in adults.
Tektonidou MG, Andreoli L, Limper M, et al.
Annals of the rheumatic diseases 2019; (78(10)):1296-1304 doi:10.1136/annrheumdis-2019-215213.
PMID: 31092409 - 17
Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome.
Miyamae T, Kawabe T
Journal of clinical medicine 2021; (10(6)) doi:10.3390/jcm10061240.
PMID: 33802787
This page is for informational purposes only and does not constitute medical advice. Ask your child’s pediatrician or a pediatric hematologist or rheumatologist about your family’s situation and any urgent symptoms.
Get notified when new evidence is published on familial antiphospholipid syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.